Cirrus Pharmaceuticals Adds cGMP Suite
Facility will provide manufacturing services for inhalation, liquids, topicals and oral solids dosage forms
Pharmaceutical contract development and manufacturing services provider Cirrus Pharmaceuticals, a Kemwell company, has announced that it will invest in a flexible cGMP suite in its facility in Research Triangle Park, NC. The addition of the suite will allow the company to offer cGMP manufacturing services for inhalation, liquids, topicals and oral solids dosage forms. The facility is scheduled to be operational in April 2015.
Kemwell’s R&D division employs 175 scientists worldwide and provides formulation development, analytical development, validation and clinical trial manufacturing.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Understanding the Variability in Bioburden Test Results in Biomanufacturing
May 7th 2025This article explores the impact of test volume, microbial distribution, and dilution errors on bioburden testing variability. It presents statistical approaches to estimate percentage error and discusses strategies to optimize microbial enumeration techniques in biopharmaceutical quality control.
Trump Directs FDA, EPA to Reduce Regulatory Barriers to Domestic Pharma Manufacturing
May 7th 2025The White House is instructing FDA to increase fees for and inspections of foreign drug manufacturing plants and reduce the time required to approve such sites that will be newly constructed in the US.
